SCHEMBL7499875

SCHEMBL7499875

COc1ccc(-c2ccc(-c3c(Br)oc4ccccc34)cc2)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 3/20 0.56
CA1 P00915 1/20 0.56
CA2 P00918 1/20 0.56
KDM4E B2RXH2 5/20 0.51
MAPT P10636 5/20 0.51
RAB9A P51151 4/20 0.51
ALDH1A1 P00352 3/20 0.51
LMNA P02545 3/20 0.51
NPC1 O15118 3/20 0.51
CYP3A4 P08684 2/20 0.51
HSD17B10 Q99714 2/20 0.51
ABCG2 Q9UNQ0 1/20 0.51
TNKS O95271 1/20 0.51
TP53 P04637 1/20 0.51
GLA P06280 1/20 0.51
THRB P10828 1/20 0.51
HPGD P15428 1/20 0.51
KCNA5 P22460 1/20 0.51
KCNH2 Q12809 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27948316 0.81 ABCG2 (0.66) MAOBCA1CA2KDM4EMAPT
SCHEMBL11743676 0.80 ALDH1A1 (0.60) MAOBCA1CA2KDM4EMAPT
SCHEMBL11663639 0.79 CA1 (0.49) CA1CA2KDM4EMAPTRAB9A
SCHEMBL7503917 0.79 PTPN1 (0.57) MAOBKDM4ERAB9AALDH1A1NPC1
SCHEMBL29406889 0.77 CYP2C9 (0.55) MAOBCA1CA2KDM4EMAPT
SCHEMBL7500675 0.76 PTPN1 (0.65) KDM4EALDH1A1LMNAHPGDSMN1; SMN2
SCHEMBL7876432 0.76 MAPT (0.52) MAOBCA1CA2KDM4EMAPT
SCHEMBL31511409 0.76 MAOB (0.72) MAOBCA1CA2KDM4EMAPT
SCHEMBL7463411 0.76 MAOB (0.72) MAOBCA1CA2KDM4EMAPT
SCHEMBL20277286 0.75 MAOB (0.56) MAOBCA1CA2KDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1077967-B1 BIPHENYL OXO-ACETIC ACIDS USEFUL IN THE TREATMENT OF INSULIN RESISTANCE AND HYPERGLYCEMIA WYETH CORP (US) 2002-12-04 EP disclosed
US-6391897-B2 (4'-BENZOFURAN-3-YL-BIPHENYL-4-YLOXY)-ACETIC ACID, FOR EXAMPLE; INHIBIT PROTEIN-TYROSINE PHOSPHATASES (PTPASES) AMERICAN HOME PRODUCTS CORPORATION 2002-05-21 US disclosed
US-6369072-B2 Biphenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia AMERICAN HOME PRODUCTS CORPORATION 2002-04-09 US disclosed
US-20010053785-A1 Biphenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia WYETH 2001-12-20 US disclosed
US-20010041715-A1 Biphenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia AMERICAN HOME PRODUCTS 2001-11-15 US disclosed
US-6232322-B1 SUCH AS (4'-BENZOFURAN-3-YL-BIPHENYL-4-YLOXY)-ACETIC ACID OR SALT AMERICAN HOME PRODUCTS CORPORATION 2001-05-15 US disclosed
EP-1077967-A2 BIPHENYL OXO-ACETIC ACIDS USEFUL IN THE TREATMENT OF INSULIN RESISTANCE AND HYPERGLYCEMIA AMERICAN HOME PRODUCTS CORPORATION (US) 2001-02-28 EP disclosed
WO-1999058518-A2 BIPHENYL OXO-ACETIC ACIDS USEFUL IN THE TREATMENT OF INSULIN RESISTANCE AND HYPERGLYCEMIA AMERICAN HOME PRODUCTS CORPORATION (US) 1999-11-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010053785-A1 Biphenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia GPR119, INSR, IAPP MAOB 540/4885CA1 3109/4885CA2 1263/4885
US-20010041715-A1 Biphenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia GPR119, INSR, IAPP MAOB 540/4885CA1 3109/4885CA2 1263/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.